A recent prospective observational study from the Nordic Rheumatic Diseases Strategy Trials and Registries showed that obesity was associated to a reduced effectiveness of treatments for RA, including biologic DMARDs such as selective T‐cell co‐stimulation modulators and IL‐6 inhibitors [53]. The gene discussed is IL6; the disease is obesity due to melanocortin 4 receptor deficiency.